CAN008 prolongs overall survival in patients with newly diagnosed GBM characterized by high tumor mutational burden

CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses

(2023) Mingyu He et al.   SCIENCE

Immunotherapy for glioblastoma: the promise of combination strategies

(2022) Mathilde Bausart et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases

(2022) Vesna Risso et al.   Cell Death & Disease

The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression

(2022) Ye Yuan et al.   Cancer Communications

Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives

(2021) Ana Laura V. Alves et al.   Stem Cell Research & Therapy

Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study

(2021) Kuo-Chen Wei et al.   Scientific Reports

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

(2020) Aurélien Marabelle et al.   LANCET ONCOLOGY

Tumor Mutation Burden and Cancer Treatment

(2020) Michael J. Fusco et al.   JAMA Oncology

Theranostic Strategy of Focused Ultrasound Induced Blood-Brain Barrier Opening for CNS Disease Treatment

(2019) Ko-Ting Chen et al.   Frontiers in Pharmacology

Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients

(2019) Chunchao Zhu et al.   Journal of Translational Medicine

Molecular targeted therapy of glioblastoma

(2019) Emilie Le Rhun et al.   CANCER TREATMENT REVIEWS

Dp71 Expression in Human Glioblastoma

(2019) Simona Ruggieri et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy

(2019) Michael Naidoo et al.   MOLECULAR NEUROBIOLOGY

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

(2018) Jonas Blaes et al.   MOLECULAR CANCER RESEARCH

NGSCheckMate: software for validating sample identity in next-generation sequencing studies within and across data types

(2017) Sejoon Lee et al.   NUCLEIC ACIDS RESEARCH

CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells

(2016) M Drachsler et al.   Cell Death & Disease

Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro

(2015) Christian Merz et al.   ANTI-CANCER DRUGS

Biomarkers in Cancer Immunotherapy

(2015) Ton N. Schumacher et al.   CANCER CELL

The role of CD95 and CD95 ligand in cancer

(2015) M E Peter et al.   CELL DEATH AND DIFFERENTIATION

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target

(2014) Melanie Jackson et al.   CARCINOGENESIS

A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

(2014) W. Wick et al.   CLINICAL CANCER RESEARCH

Human Circulating CD4+CD25highFoxp3+ Regulatory T Cells Kill Autologous CD8+ but Not CD4+ Responder Cells by Fas-Mediated Apoptosis

(2014) L. Strauss et al.   JOURNAL OF IMMUNOLOGY

CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer

(2013) M. Malleter et al.   CANCER RESEARCH

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients

(2012) Jochen Tuettenberg et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

CD95 promotes tumour growth

(2010) Lina Chen et al.   NATURE

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma

(2008) Susanne Kleber et al.   CANCER CELL